Share the Savings

Patients share the costs for their medicines. They should share the savings, too.

Robust negotiations between biopharmaceutical companies and insurers often result in significant rebates and discounts. According to a recent study from the Berkeley Research Group, more than a third of the list price for brand medicines is rebated back to payers and the supply chain.

However, unlike care received at an in-network hospital or physician’s office, negotiated discounts for medicines are not shared with patients with high deductibles or coinsurance. A new analysis from Amundsen Consulting found more than half of commercially insured patients’ out-of-pocket spending for brand medicines is based on the full list price. 

Insurers should share more of these rebates with patients.  Providing access to discounted prices at the point-of-sale could dramatically lower patients’ out-of-pocket costs.

Get the facts and find out where the discounts are going.

latest from the


  • Guest Post: Following my stroke, having access to ground-breaking medical innovation has never been more important

  • IP Explained: Three forms of IP protections for medicines

  • Three reasons the Senate Finance package is the wrong approach for patients

  • 340B Spotlight: How for-profit middlemen are taking advantage of a program meant to support nonprofit entities and patients

  • New analysis: Government intervention in Part B threatens patient access to medicines

  • Three things to know about the Part D GAO report

  • Four Things You Should Know About AARP

  • What they’re saying: Safety is top concern for recent drug importation proposal

  • IP Explained: How patents support innovation throughout the biopharmaceutical lifecycle

  • ICYMI: Canadian government, stakeholders voice concerns with drug importation proposals

  • IP Explained: Understanding biopharmaceutical innovation

  • IP Explained: Why IP protections are important for biologic medicines

  • Myvideopays member companies invested nearly $80 billion in R&D last year

  • Setting the record straight on international reference pricing

  • Four states adopt first-in-the-nation laws to protect patients from surprise insurer practices

  • New Let’s Talk About Cost TV ad asks: Why aren’t patients sharing in savings at the pharmacy counter?

  • Study finds hospitals continue to mark up medicines up to 500% of their cost

  • Three reasons why the latest Rx Savings Solutions analysis is misleading

  • No matter how you structure it, government arbitration is wrong for Medicare drug coverage

  • Myvideopays responds to Florida’s request for information on drug importation